SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors anticipate a major catalyst from the REGAL Phase 3 trial, with active discussion centered on imminent survival data, institutional positioning, and buyout potential. The community remains polarized, with vocal longs betting on a structural paradigm shift in cancer treatment while skeptical voices highlight clinical trial uncertainties and the speculative nature of recent price volatility.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's has become a viral focal point for retail traders seeking a short squeeze, driven by significant short interest, undervalued fundamentals, and community-led efforts to boost store traffic. Investors are actively discussing the strategy of holding common shares and avoiding stop-loss orders to counter volatility while drawing parallels to historical meme stock surges.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is experiencing a sharp institutional-driven rebound, fueled by massive rebalancing inflows and high-profile long-term LEAP acquisitions from notable investors. While some traders view this as a potential intermediate-term bottoming signal, the community remains divided between those seeing a structural AI-led turnaround and skeptics warning that the current momentum may be a technical relief rally before further volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently a central focus for traders as the stock experiences high volatility amid its transition from the Russell 2000 to the Russell 1000 index, triggering heavy institutional rebalancing and mechanical trading volume. The broader community sentiment remains polarized, with bullish investors emphasizing the company's role in the AI data center power infrastructure buildout and growing hyperscaler demand, while bears point to stretched valuations and high share dilution.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors debate the impact of high-profile insider selling against the company's aggressive expansion into military USV and drone technology. The community is focused on the timing of potential government contract awards, weighing management's long-term production build-out strategy against ongoing frustrations regarding revenue transparency and stock dilution.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is trending following the FDA approval of Lumvoa, a new treatment for Thyroid Eye Disease (TED), which community members believe provides a competitive advantage over existing therapies. Investors are actively discussing the potential for market share capture, upcoming conference call details regarding launch metrics, and speculation about future acquisition interest given the company's strengthened clinical portfolio.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The Vanguard S&P 500 ETF is trending as investors debate the merit of broad-market exposure versus targeted rotation into AI, memory, and semiconductor growth plays. The community is actively discussing the potential impact of high-profile IPOs, ongoing geopolitical tensions in the Middle East, and the effectiveness of passive long-term compounding amid market volatility.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending due to reports that it is in advanced talks to acquire Terns Pharmaceuticals, a move intended to bolster its oncology pipeline ahead of the significant upcoming patent expiration for Keytruda. The community is actively discussing how this strategic acquisition and other potential M&A activity within the biotech sector are shaping market positioning for large-cap healthcare players.

TOSHI

TOSHI is trending as investors analyze its shift from a meme coin toward AI-integrated utility, with the community actively discussing potential supply-burning mechanisms and upcoming ecosystem expansions. Sentiment remains divided, as supporters highlight accumulation opportunities during consolidation while others express frustration over recent price volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector, represented by the SPDR S&P Biotech ETF (XBI), is currently experiencing a strong bullish rotation as investors shift capital into the sector for its potential in revolutionary research and its role as a defensive hedge against broader market volatility. The community is actively discussing key catalysts like institutional M&A activity and the potential for clinical trial breakthroughs, while closely debating the high-risk, high-reward nature of individual pipeline stocks compared to the relative stability of the broader index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NIO Stock Tracks Worst Month In 2026: EV Maker Pursues Hong Kong Primary Listing Upgrade To Expand Investor Base 

Equity

The move could make Nio eligible for the Stock Connect program, allowing mainland Chinese investors to buy its Hong Kong-listed shares.

Tesla Under Pressure Again: Is the Bear Case Getting Overplayed?  

TSLA's safety probe adds pressure, but energy growth, improving overseas deliveries, and FSD approvals may make selling the stock premature.

Automakers Race Into Humanoid Robots As Timeline For Blue-Collar Job Disruption Emerges

Automakers Race Into Humanoid Robots As Timeline For Blue-Collar Job Disruption Emerges

 Bernstein analyst Eunice Lee is out with a fascinating note explaining why automakers are making a mad dash into the world of humanoid robotics, arguing that their manufacturing scale, supply-chain...

China's Alibaba Unveils AI Brains Designed To Power The Next Generation Of Robots

China's Alibaba Unveils AI Brains Designed To Power The Next Generation Of Robots

 Authored by Jijo Malayil via Interesting Engineering,

Chinese firm Alibaba has launched its first embodied AI model family, which links large language models with real-world robotic actions.
The...

XPENG X9 Tops Range and Charging Performance in World's Largest EV Test

XPENG X9 Tops Range and Charging Performance in World's Largest EV Test XPENG X9 Tops Range and Charging Performance in World's Largest EV Test PR Newswire AMSTERDAM, June 12, 2026 11% above WLTP to 646 km and 12m55s charge secure double victory at NAF El Prix Summer 2026AMSTERDAM, June 12, 2026...

Tesla Challenger XPeng’s CEO Takes Over Robotics Division After Key Executive Departure – XPEV Slides For Sixth Straight Session

According to a Reuters report, CEO He Xiaopeng will take over leadership of XPeng's robotics division immediately as the company moves toward starting mass production of its humanoid robots by the end of the year.

Is NIO's Path to Positive Operating Profit Becoming Clear?

NIO targets positive non-GAAP operating profit in 2026, backed by disciplined R&D spending, higher efficiency and plans to improve operating leverage.


Is NIO's Premium Positioning Creating a Lasting Advantage?

NIO is strengthening its premium brand appeal in China with higher ASPs, growing market share and a user-focused ecosystem that supports differentiation.


XPEV Stock Falls On $500M AI Bet For Self-Driving Tech — Exec Says Xpeng Is Following Google’s Pixel Playbook 

Xianming Liu, head of XPeng's General Intelligence Center, told Electrek that the company spends roughly RMB 300 million a month training AI models for autonomous driving.

Can NIO Achieve 17-18% Vehicle Margins in 2026 Amid Cost Pressures?

NIO targets 17-18% vehicle margins despite rising EV costs, leaning on high-margin ES8/ES9 models, pricing discipline and supply-chain efforts.


XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$12.09
Prev Close	$12.19
Open	$11.80
Dividend Yield	0.00%
50-Day Moving Average	$15.64
Beta	1.20
Avg. Volume	7.07M
PE Ratio	-35.73

52-Week High	$28.24
52-Week Low	$11.77
Market Capitalization	$9.45B
EPS (Annual)	-$0.1665
Price to Book	2.80
Revenue Per Employee	$536,745.29

Feed

News

Sentiment

Earnings

Fundamentals

Info

XPEVXPeng Inc - ADR

Latest XPEV News